Skip to content

Collegium Pharmaceutical, Inc. COLL Symproic — Finite-Lived Intangible Assets, Net

Other product segments

Jornay PM
$502.97M-14.3%
Belbuca
$56.54M-57.1%
Symproic and other
$42.5M-14.6%

Similar metrics at other companies

Ducommun logo
DCOStructural Systems — Finite-Lived Intangible Assets, Net
$90.94M-7.6%
Morgan Stanley logo
MSInstitutional Securities — Finite-Lived Intangible Assets, Net
$21M-22.2%
Ducommun logo
DCOElectronic Systems — Finite-Lived Intangible Assets, Net
$37.2M-20.0%
State Street logo
STTInvestment Management — Finite-Lived Intangible Assets, Net
$17M-32.0%
Howmet Aerospace logo
HWMFinite Lived Intangible Assets - Gross
$958M-1.4%
Mannkind logo
MNKDISPERSE License — Finite Lived Intangible Assets Net
$4.3M

Other financials

Income statement

See full
Revenue$193.5M+8.9%
Gross profit$117.2M+20.5%
Operating income$30.9M+42.5%
Net income$14.5M+500%
EPS (diluted)$0.40+471%

Balance sheet

See full
Cash & equivalents$289.6M+147%
Total debt$5.2M-19.5%
Total equity$312.4M+33.3%
Total assets$1.7B+1.3%

Cash flow

See full
Operating cash flow$57.1M+3.1%
CapEx$270.0K-66.2%
Free cash flow$56.8M+4.1%

Valuation

See full
Market cap$1.15B+20.4%
Enterprise value$869.67M+2.5%
P/E15.4×-6.4×
P/S1.5×0.0×

Profitability

See full
Gross margin60.7%+3.0pp
Operating margin23.7%+2.3pp
Net margin9.4%+2.8pp
FCF margin41.4%+10.4pp

Returns & leverage

See full
Return on equity27.4%+8.2pp
Debt / equity0.0×
Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.

The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, net?
Collegium Pharmaceutical, Inc. (COLL) reported symproic — finite-lived intangible assets, net of $40.68M in Q1 2026.
How has Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, net changed year-over-year?
Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, net decreased by 15.2% year-over-year, from $47.96M to $40.68M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, net?
Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, net has grown at a -12.3% compound annual growth rate (CAGR), from $268.35M to $180.92M.
What does symproic — finite-lived intangible assets, net mean?
The carrying value of finite-lived intangible assets associated with Symproic, calculated as the gross cost minus accumulated amortization and any impairment charges. It represents the remaining unamortized economic value of the asset on the balance sheet.